Back to Newsroom

Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations

THOUSAND OAKS, Calif. and PASADENA, Calif. (Sept. 29, 2016) — Amgen (NASDAQ: AMGN) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowhead’s proprietary subcutaneous RNAi delivery platform. RNAi molecules may be designed to target and shut down specific gene products that contribute to various diseases.

Click here to read the full release